Cargando…
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
Antituberculosis (anti-TB) drug development is dependent on informative trials to secure the development of new antibiotics and combination regimens. Clofazimine (CLO) and pyrazinamide (PZA) are important components of recommended standard multidrug treatments of TB. Paradoxically, in a phase IIa tr...
Autores principales: | Faraj, Alan, Svensson, Robin J., Diacon, Andreas H., Simonsson, Ulrika S. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179644/ https://www.ncbi.nlm.nih.gov/pubmed/32122887 http://dx.doi.org/10.1128/AAC.01905-19 |
Ejemplares similares
-
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
por: Mockeliunas, Laurynas, et al.
Publicado: (2023) -
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023) -
Clofazimine for the treatment of tuberculosis
por: Stadler, Jacob A. M., et al.
Publicado: (2023) -
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022) -
Clofazimine pharmacokinetics in patients with TB: dosing implications
por: Abdelwahab, Mahmoud Tareq, et al.
Publicado: (2020)